Q4 2024 Aquestive Therapeutics Inc Earnings Call Transcript

Mar 6, 2025 / 01:00 PM GMT

Release Date Price: $2.58 (-7.53%)

Transcript 10-K8-K

Key Points

Positve

Aquestive Therapeutics Inc (AQST) has begun the FDA filing process for its Afilm epinephrine sublingual film, with expectations for NDA acceptance by June 2025.
The company is on track to launch Anafilm in the first quarter of 2026, aligning with the allergy season, which could enhance market penetration.
Pediatric studies for Anafilm have progressed as expected, with data supporting a product label similar to existing EpiPen autoinjectors.
Aquestive Therapeutics Inc (AQST) has strengthened its balance sheet by raising over $78 million from institutional healthcare investors.
The company is preparing for potential international market expansion, targeting submissions in the EU, UK, and Canada.

Negative

Total revenue decreased by 10% in Q4 2024 compared to Q4 2023, primarily due to declines in license and royalty revenue.
Research and development expenses increased significantly, driven by clinical trial costs for NFLM and AQST 108 programs.
Selling, general, and administrative expenses rose sharply due to increased commercial spending and regulatory fees.
Aquestive Therapeutics Inc (AQST) reported a net loss of $17.1 million for Q4 2024, a substantial increase from the $8.1 million loss in Q4 2023.
The company faces legal challenges regarding Libervan's market exclusivity, which could impact its availability and revenue potential.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

AQST.OQ - Aquestive Therapeutics Inc
Q4 2024 Aquestive Therapeutics Inc Earnings Call
Mar 06, 2025 / 01:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good day and thank you for standing by. Welcome to the 4th quarter of 2024 request of Therapeutics Earnings conference call. At this time, all participants are on a listen-only mode. After the speaker's presentation, there'll be a question and answer session. To ask a question during the session, you need to press 11 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press 11 again. Please be advised that these conferences are being recorded. I would not like to end the conference over your speaker today, Brian Core, please go ahead.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.